Last reviewed · How we verify

Sacituzumab govetican

Henry Ford Health System · Phase 1 active Small molecule

Sacituzumab govetican is a Small molecule drug developed by Henry Ford Health System. It is currently in Phase 1 development. Also known as: Trodelvy.

At a glance

Generic nameSacituzumab govetican
Also known asTrodelvy
SponsorHenry Ford Health System
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sacituzumab govetican

What is Sacituzumab govetican?

Sacituzumab govetican is a Small molecule drug developed by Henry Ford Health System.

Who makes Sacituzumab govetican?

Sacituzumab govetican is developed by Henry Ford Health System (see full Henry Ford Health System pipeline at /company/henry-ford-health-system).

Is Sacituzumab govetican also known as anything else?

Sacituzumab govetican is also known as Trodelvy.

What development phase is Sacituzumab govetican in?

Sacituzumab govetican is in Phase 1.

Related